Broad Institute

OCTOBER 16, 2024

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines By Corie Lok October 16, 2024 Breadcrumb Home F. William Studier of Brookhaven National Laboratory in a ceremony and symposium at the Broad Institute on September 17, 2024.

Vaccine 64

Vaccine RNA Laboratories Molecular Biology 64

The Pharma Data

DECEMBER 2, 2020

The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates. This License Agreement represents an important corporate milestone.

Licensing 52

Licensing Licensing Vaccine Virus 52

The Pharma Data

SEPTEMBER 7, 2021

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School. The vaccine currently being tested stimulates the body’s immune system to produce antibodies to oxycodone.

Clinical Trials 52

Clinical Trials Vaccine Trials Medical Schools 52

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production. Vivera Pharmaceuticals, Inc.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

MARCH 14, 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the Company is continually monitoring the safety of its vaccine. COVID-19 Vaccine AstraZeneca , formerly AZD1222.

Vaccine 52

Vaccine Virus Licensing Licensing 52

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. The world has changed due to its impact – and the race to discover a vaccine is crucial for our return to normalcy.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

The Pharma Data

SEPTEMBER 18, 2020

Around one in seven patients who have received Russia’s vaccine against COVID-19 have displayed side-effects in clinical studies, according to the country’s Health Minister. The Health Minister defended the development programme, arguing that the vaccine has navigated a platform of evaluation that has been successfully used for past vaccines.

Vaccine 52

Vaccine Laboratories Trials Drugs 52

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. mRNA vaccines include the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine.

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

The Pharma Data

SEPTEMBER 16, 2020

Russia has signed a deal with an Indian pharma firm to test and deliver 100 million doses of its controversial Sputnik V vaccine for COVID-19 to the nation’s citizens as it sees its death toll surge to overtake Brazil as the second-worst hit country on Earth after the US.

Vaccine 52

Vaccine Clinical Trials Laboratories Trials 52

The Pharma Data

SEPTEMBER 22, 2020

Clinical trials testing Russia’s Sputnik-V coronavirus vaccine in India could begin in the next few weeks, according to Indian pharma firm Dr Reddy’s Laboratories Ltd. . The RDIF have said that vaccine deliveries could begin in late 2020, but Sapra feels it could take longer as the clinical trial process will take months. .

Clinical Trials 52

Clinical Trials Vaccine Trials Laboratories 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

Codon

AUGUST 26, 2024

Brian Wang (co-founder of the nonprofit Panoplia Laboratories ) outlines his approach to making broad-spectrum antivirals. He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 97

RNA Virus DNA Vaccine 97

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. of the mice that were vaccinated with the T-cell-based vaccine survived, while only one of the control-group mice survived.

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

The Connected Lab

APRIL 29, 2020

Instrument connectivity is often the most time consuming and technically challenging component of a laboratory setup or laboratory information management system (LIMS) implementation. For laboratories on the front line of the COVID-19 fight, time spent connecting instruments and software is time lost fighting the disease.

Laboratories 52

Laboratories Vaccine Research Laboratories Treatment 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

APRIL 1, 2021

Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine. Sanofi announces investment of more than €600 million to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States and Europe.

Vaccine 52

Vaccine Government Science Production 52

The Pharma Data

FEBRUARY 18, 2022

Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia to establish mRNA vaccine production. At the European Union – African Union summit in Brussels today WHO Director-General, Dr Tedros Adhanom Ghebreyesus, announced the first six countries that will receive the technology needed to produce mRNA vaccines on the African continent.

Vaccine 52

Vaccine Production Clinical Research Laboratories 52

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Annaliesa is a world-class scientist with a track record of delivering both vaccines and therapeutics in pioneering new areas of science and where there is urgent unmet need.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. One dose of the Sputnik V vaccine will cost less than $10 for international markets.

Virus 52

Virus Vaccine International Immune Response 52

PLOS: DNA Science

MAY 16, 2024

That’s thanks to accelerated genome sequencing technologies, expanded laboratory capabilities, and interacting infrastructure on a global level. Had we grown complacent in a world freed from a list of once-deadly infectious diseases, thanks largely to vaccines and other public health measures? Work on vaccines ensued too.

Virus 98

Virus DNA RNA Vaccine 98

The Pharma Data

MAY 7, 2021

During an early May meeting, the European Medicines Agency’s safety committee concluded two reviews of safety signals related to COVID-19 vaccines, while it continued following other vaccine-related “topics of interest.” These included reports of heart muscle inflammation after receipt of the Pfizer-BioNTech vaccine. .

Vaccine 40

Vaccine RNA Laboratories Production 40

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Pfizer-BioNTech Laboratory Study.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

OCTOBER 19, 2020

.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The new vaccine remains stable for a time in the refrigerator. WEDNESDAY, Jan. 13 in the New England Journal of Medicine.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

Drug Target Review

DECEMBER 6, 2023

Shifting focus to cancer vaccines in Chapter 3, we look at the power of ‘rational vaccinology,’ showcasing a modified tuberculosis vaccine with potential applications in bladder cancer treatment. Join us as we navigate the forefront of cancer research, offering first hand insights into transformative breakthroughs.

Research 64

Research Pharmacy Vaccine Laboratories 64

The Pharma Data

NOVEMBER 16, 2020

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. The majority of adverse events were mild or moderate in severity.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

Codon

AUGUST 27, 2024

The initial BioWatch machines required off-site laboratory analysis, which means a trained technician had to go to each machine, collect samples, and then study those samples in a laboratory. New Yorkers wait to receive a monkeypox vaccine. At least nine laboratories outside the U.S.

DNA 97

DNA Laboratories Hospitals Virus 97

The Pharma Data

NOVEMBER 16, 2020

Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. percent efficacy rate.

Vaccine 40

Vaccine Government Clinical Trials Disease 40

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Nadine Rouphael, M.D.,

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

KIF1A

MARCH 9, 2024

During her undergraduate studies, she worked on heart disease research in Chi Kueng Lam’s laboratory at the University of Delaware. Currently, Wenxu is part of Cornish Lab at Columbia University, working on theranostic cells and synthetic biology of yeast vaccine. For example, KIF1A is included on Invitae’s HSP gene panel.

Laboratories 111

Laboratories Science Research Disease 111

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

PPD

JULY 6, 2023

From oncology clinical research to vaccine development , successfully executing and overseeing the many moving parts of a clinical trial may become overwhelming for sponsors to handle alone. Undoubtedly, a CRO’s ability to respond to increased urgency by assuring certainty and speed in project delivery is the gold standard.

Clinical Trials 98

Clinical Trials Trials Drug Development Testimonials 98

Codon

DECEMBER 12, 2024

” In 2022, the same laboratory repeated the process for RNA polymerase, an enzyme that transcribes DNA into RNA as the first step in protein synthesis. If bacteria do escape from the laboratory, then many of the cells will naturally be killed by predators, like bacteriophages and protists, present in the environment.

RNA 102

RNA DNA Vaccine Virus 102

KIF1A

MAY 4, 2024

During her undergraduate studies, she worked on heart disease research in Chi Kueng Lam’s laboratory at the University of Delaware. Currently, Wenxu is part of Cornish Lab at Columbia University, working on theranostic cells and synthetic biology of yeast vaccine. The post #ScienceSaturday: May 4, 2024 appeared first on KIF1A.

Science 116

Science Medical Schools Research RNA 116